Reve Technologies, Inc. (BSSP)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2014 | -181.48 Thousand USD | -128.33% |
| 2013 | -79.48 Thousand USD | -87.33% |
| 2012 | -42.42 Thousand USD | 52.04% |
| 2011 | -88.47 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2015 Q1 | -109.8 Thousand USD | -91.31% |
| 2015 Q2 | -201.97 Thousand USD | -83.94% |
| 2015 Q3 | -29.77 Thousand USD | 85.26% |
| 2014 Q2 | -46.21 Thousand USD | -40.71% |
| 2014 Q4 | -57.39 Thousand USD | -27.45% |
| 2014 Q3 | -45.03 Thousand USD | 2.56% |
| 2014 FY | -181.48 Thousand USD | -128.33% |
| 2014 Q1 | -32.84 Thousand USD | -18.4% |
| 2013 FY | -79.48 Thousand USD | -87.33% |
| 2013 Q4 | -27.74 Thousand USD | 9.72% |
| 2013 Q2 | -16.86 Thousand USD | -306.78% |
| 2013 Q1 | -4147.00 USD | 61.35% |
| 2013 Q3 | -30.72 Thousand USD | -82.14% |
| 2012 FY | -42.42 Thousand USD | 52.04% |
| 2012 Q3 | -9274.00 USD | -5.69% |
| 2012 Q2 | -8775.00 USD | 35.71% |
| 2012 Q1 | -13.65 Thousand USD | -72.76% |
| 2012 Q4 | -10.72 Thousand USD | -15.69% |
| 2011 Q2 | -9069.00 USD | -84.22% |
| 2011 Q1 | -4923.00 USD | 0.0% |
| 2011 FY | -88.47 Thousand USD | 0.0% |
| 2011 Q3 | -66.58 Thousand USD | -634.16% |
| 2011 Q4 | -7901.00 USD | 88.13% |
| 2010 Q3 | -1038.00 USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 86.41% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 96.402% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 98.983% |
| Nascent Biotech, Inc. | -2.22 Million USD | 91.861% |
| Rebus Holdings, Inc. | -664 Thousand USD | 72.668% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 100.222% |
| Qrons Inc. | -643.67 Thousand USD | 71.805% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | 53.414% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 99.673% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 56.319% |
| Skye Bioscience, Inc. | -13.67 Million USD | 98.673% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 99.747% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 103.693% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | 30.658% |
| SQZ Biotechnologies Company | -75.82 Million USD | 99.761% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 93.633% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 88.185% |
| Mesoblast Limited | -84.14 Million USD | 99.784% |
| Marizyme, Inc. | -34.08 Million USD | 99.468% |
| Genus plc | 6.4 Million USD | 102.836% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 101.863% |
| Pharming Group N.V. | -4.87 Million USD | 96.281% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 90.864% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 80.514% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 97.827% |
| ContraFect Corporation | -56.88 Million USD | 99.681% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 96.015% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 87.055% |
| IMV Inc. | -38.67 Million USD | 99.531% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 93.403% |
| MultiCell Technologies, Inc. | -722.81 USD | -25008.258% |
| ONE Bio Corp. | 13.68 Million USD | 101.326% |
| Accustem Sciences Inc. | -3.74 Million USD | 95.156% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 99.692% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | 62.43% |
| Q BioMed Inc. | -3.44 Million USD | 94.733% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 105.127% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 93.093% |
| Biomind Labs Inc. | -1 Million USD | 82.024% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 99.67% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 93.745% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 97.27% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 90.266% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -505.919% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 98.856% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 90.609% |
| GB Sciences, Inc. | -1.42 Million USD | 87.224% |
| Alpha Cognition Inc. | -9.7 Million USD | 98.13% |
| HST Global, Inc. | -140.9 Thousand USD | -28.798% |
| CSL Limited | 3.7 Billion USD | 100.005% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 83.867% |
| Halberd Corporation | -75.05 Thousand USD | -141.819% |
| Enzolytics Inc. | -2.14 Million USD | 91.554% |
| Agentix Corp. | -1.37 Million USD | 86.77% |
| Resverlogix Corp. | -12.74 Million USD | 98.576% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 94.272% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.957% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 82.616% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 93.784% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 88.509% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 94.67% |
| AVAX Technologies, Inc. | 6.69 Million USD | 102.712% |
| Zenith Capital Corp. | -8.94 Million USD | 97.971% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.956% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -941.76% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 92.608% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -5.816% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 90.947% |
| Kadimastem Ltd | -3.04 Million USD | 94.031% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 81.557% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 85.551% |
| BioStem Technologies, Inc. | -7.77 Million USD | 97.667% |
| Oncology Pharma Inc. | - USD | Infinity% |
| LadRx Corporation | -3.82 Million USD | 95.254% |
| Cell Source, Inc. | -4.32 Million USD | 95.804% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 73.581% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 73.581% |
| NovAccess Global Inc. | -2.46 Million USD | 92.643% |
| Affymax, Inc. | -15.04 Million USD | 98.794% |
| Itoco Inc. | -919.14 Thousand USD | 80.255% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 95.718% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 83.782% |
| Mobile Lads Corp. | -554.55 Thousand USD | 67.273% |
| CytoDyn Inc. | -18.05 Million USD | 98.995% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -621.037% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | 17.536% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | 67.863% |
| SYBLEU INC | -149.18 Thousand USD | -21.655% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 90.008% |
| International Stem Cell Corporation | -663 Thousand USD | 72.627% |
| Bioxytran, Inc. | -3.82 Million USD | 95.249% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -244.766% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -792.257% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 99.5% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 88.783% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | 75.336% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 94.166% |
| Neutra Corp. | -229.48 Thousand USD | 20.917% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 98.965% |
| PureTech Health plc | -146.19 Million USD | 99.876% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 99.156% |
| IXICO plc | -1.43 Million USD | 87.371% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 98.088% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 99.851% |
| CSL Limited | 3.81 Billion USD | 100.005% |
| Cellectis S.A. | -108.85 Million USD | 99.833% |